Sistemic Announces Customer Agreement with Cytori Therapeutics

| Print |
Wednesday, 20 June 2012 09:00 (UTC + 2)

Sistemic_logo

Cytori to Utilize Sistemic’s SistemQC™ to Strengthen Understanding of  Mechanisms & Support Design of Next-Generation Cell Therapies

Boston, Mass., USA, June 20, 2012 / B3C newswire /Sistemic Ltd. (“Sistemic”), a leading provider of microRNA-based problem-solving services and kit-based products, has formed a customer relationship with Cytori Therapeutics (“Cytori”). Cytori will utilize Sistemic’s proprietary SistemQC™  technology platform in its U.S. cardiac cell therapy clinical trial to molecularly characterize adipose-derived stem and regenerative cells (ADRCs).

“Research has shown that within adipose tissue, as well as other cell sources like bone marrow, there are multiple distinct cell types that can contribute to efficacy,” commented Sistemic chairman and CEO Jim Reid. “Cytori selecting our SistemQC serves as another validation of our technology, particularly its flexibility to characterize a wide variety of cells for identity and potency, on a molecular level. We could not be more pleased to have reached this agreement with Cytori.”

The announcement was made at the 2012 Bio International Convention in Boston, where Mr. Reid is moderating a panel on stem cell therapeutics featuring leaders from the industry, on Wednesday, June 20, at the Boston Convention Center.

“SistemQC will be incorporated into our clinical development to understand which cell types within our Celution® System’s autologous heterogeneous population of ADRCs are the greatest contributors to efficacy,” said Douglas Arm, Ph.D., Senior Vice President Operations at Cytori. “With Sistemic’s novel technology, we can strengthen the mechanistic understanding of our cell output and at the same time support the design of next-generation cell therapies.”


About Sistemic Ltd
Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™.

About Cytori
Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family.


Contact

Dr. Verna McErlane
Director of Commercial Operations
+ 44 (0)7855 376 358
This e-mail address is being protected from spambots. You need JavaScript enabled to view it